<DOC>
	<DOCNO>NCT00344526</DOCNO>
	<brief_summary>AL amyloidosis cause clonal plasma cell dyscrasia characterize progressive deposition amyloid fibrils derive monoclonal Ig light chain , lead multisystem organ failure death . The prognosis AL amyloidosis conventional treatment remain poor , Autologous stem cell transplantation ( ASCT ) AL amyloidosis produce high hematologic organ response . However , treatment-related mortality remain high report series subject selection bias .</brief_summary>
	<brief_title>Intensive Versus Conventional Treatment Patients With Primary Amyloidosis</brief_title>
	<detailed_description>A prospective randomize trial conduct compare AL amyloidosis ASCT ( melphalan 140 200 mg/m2 depend age clinical status support ASCT collect G-CSF alone ) oral regimen M-Dex ( melphalan 10 mg/m2 dexamethasone 40 mg 4 day month 18 month ) . The objective compare survival hematologic clinical response .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>70 year age biopsy proven systemic AL amyloidosis 2 prior course chemotherapy ECOG performance status &lt; 3 Informed write consent localize amyloidosis HIV seropositivity previous myelodysplasia concomitant serious disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>AL amyloidosis</keyword>
	<keyword>Autologous stem cell transplantation</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>